IAS 2013: Stem Cell Transplant Patients Remain HIV-Free [VIDEO]
- Details
- Category: Search for a Cure
- Published on Wednesday, 03 July 2013 00:00
- Written by Gregory Fowler
Two Boston men with HIV who received bone marrow transplants after a milder conditioning chemotherapy regimen continued to have undetectable virus 7 and 15 weeks after undergoing experimental treatment interruption, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
IAS 2013: Study Supports WHO Second-line HIV Treatment Guidelines for Resource-limited Countries
- Details
- Category: HIV Treatment
- Published on Wednesday, 03 July 2013 00:00
- Written by Liz Highleyman
A second-line regimen consisting of a protease inhibitor (PI) plus 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) led to good outcomes for people with HIV in Africa after initial regimen failure, according to data from the EARNEST study presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur. A NRTI-sparing regimen with raltegravir did not work significantly better, and PImonotherapy was inferior.
IAS 2013: Hepatitis C Reinfection Occurs Frequently Among Gay Men Living with HIV in London
- Details
- Category: HCV Sexual Transmission
- Published on Wednesday, 03 July 2013 00:00
- Written by Michael Carter
There is a high incidence of hepatitis C virus (HCV) reinfection among gay men living with HIV in London, results of a study published in the online edition of AIDS show. The results were also presented at 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
IAS 2013: Boston Stem Cell Transplant Recipients Now Controlling HIV Off Treatment
- Details
- Category: Search for a Cure
- Published on Wednesday, 03 July 2013 00:00
- Written by Keith Alcorn
Two people with HIV who received stem cell transplants to treat lymphoma are now controlling HIV replication without antiretroviral medication in the early weeks of treatment interruption, following the discovery that both had experienced loss of detectable HIV DNA, researchers from Boston reported Wednesday at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.
IAS 2013: iPrEx Participants Interested in Continuing HIV Pre-exposure Prophylaxis [VIDEO]
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 03 July 2013 00:00
- Written by Gregory Fowler
A majority of participants in an extension of the iPrEx pre-exposure prophylaxis (PrEP) trial said they would like ongoing open-label access to Truvada for HIV prevention, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
More Articles...
- IAS 2103: Dolutegravir Beats Raltegravir for Treatment-experienced HIV Patients [VIDEO]
- IAS 2013: Reduced Efavirenz Dose Suppresses HIV as Well as Standard Dose
- IAS 2013: Dolutegravir Superior to Raltegravir for Treatment-experienced People with HIV
- IAS 2013: AbbVie Interferon-Free Hepatitis C Combo Works Well with Reduced Ribavirin Dose
Web Design and Development by